BO
BO4.F Borregaard ASA
- Market cap
- EUR 1.46B
- P/E
- 61.1x
- P/B
- 2.57x
- ROE
- 7.7%
- Dividend yield
- 2.93%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BO4.F undervalued?
Graham numberBO4.F trades 164.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Borregaard ASA fundamental analysis
No fundamental analysis for Borregaard ASA yet.
Borregaard ASA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Borregaard ASA
Borregaard ASA engages in the development, production, and marketing of specialized biochemicals and biomaterials in Norway, rest of Europe, Asia, the United States, and internationally. It operates in three segments: BioSolutions, BioMaterials, and Fine Chemicals. The BioSolutions segment develops, produces, and sells biopolymers and biovanillin derived from lignin for agrochemicals, batteries, industrial binders, and construction, as well as to flavor and fragrance compani…
Full company profileBorregaard ASA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Borregaard ASA annual financial statements (NOK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.49B | 4.62B | 4.79B | 5.06B | 5.33B | 5.81B | 6.88B | 7.02B | 7.50B | 7.58B | 8.02B |
| Gross Profit | 2.81B | 2.94B | 2.94B | 3.17B | 3.41B | 3.65B | 4.25B | 4.48B | 4.77B | 4.92B | - |
| Operating Income | 683M | 745M | 576M | 585M | 684M | 952M | 1.19B | 1.29B | 1.31B | 1.29B | 1.40B |
| EBITDA | - | 1.05B | 925M | 976M | 1.02B | 1.36B | 1.66B | 1.79B | 1.83B | 1.62B | 1.98B |
| Net Income | 555M | 566M | 476M | 417M | 436M | 692M | 892M | 870M | 823M | 620M | 467M |
| EPS | - | 5.69 | 4.78 | 4.19 | 4.38 | 6.95 | 8.96 | 8.74 | 8.27 | 6.22 | - |
| Balance Sheet | |||||||||||
| Total Assets | 4.67B | 5.33B | 5.95B | 6.74B | 7.00B | 7.17B | 8.11B | 9.12B | 9.58B | 9.67B | 10.00B |
| Total Liabilities | 1.96B | 2.34B | 2.63B | 3.28B | 3.23B | 2.86B | 3.67B | 4.22B | 4.49B | 3.79B | 3.91B |
| Shareholders' Equity | 2.68B | 2.89B | 3.12B | 3.31B | 3.67B | 4.22B | 4.39B | 4.86B | 5.04B | 5.85B | 6.07B |
| Cash & Short-term Investments | 265M | 180M | 86.0M | 147M | 207M | 124M | 234M | 464M | 82.0M | 91.0M | 360M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.08B | 780M | 558M | 697M | 886M | 1.43B | 735M | 1.36B | 1.07B | 1.36B | 1.63B |
| Capital Expenditure | 622M | 967M | 760M | 570M | 494M | 537M | 459M | 586M | 711M | 793M | 543M |
| Free Cash Flow | - | -188M | -204M | 114M | 383M | 875M | 271M | 775M | 357M | 563M | 1.09B |
| Ratios | |||||||||||
| ROE | 20.7% | 19.6% | 15.2% | 12.6% | 11.9% | 16.4% | 20.3% | 17.9% | 16.3% | 10.6% | 7.7% |
| ROA | 11.9% | 10.6% | 8.0% | 6.2% | 6.2% | 9.7% | 11.0% | 9.5% | 8.6% | 6.4% | 4.7% |
| Net Profit Margin | 12.4% | 12.3% | 9.9% | 8.2% | 8.2% | 11.9% | 13.0% | 12.4% | 11.0% | 8.2% | 5.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Borregaard ASA dividends
- Dividend yield
- 2.93%
- Forward dividend
- 0.44 EUR
- Payout ratio
- 68.4%
- Ex-dividend date
- Apr 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | NOK 424M | 4.25 | 68.4% |
| 2024 | NOK 374M | 3.76 | 45.4% |
| 2023 | NOK 324M | 3.25 | 37.2% |
| 2022 | NOK 274M | 2.75 | 30.7% |
| 2021 | NOK 249M | 2.50 | 36.0% |
| 2020 | NOK 229M | 2.30 | 52.5% |
| 2019 | EUR 224M | 2.25 | 53.7% |
| 2018 | EUR 199M | 2.00 | 41.8% |
| 2017 | EUR 175M | 1.75 | 30.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Borregaard ASA
- Insiders 7.16%
- Institutions 58.15%
- Public & others 34.69%
- Shares outstanding 99.6M
- Free float 99.1M
Borregaard ASA company profile
- Company name
- Borregaard ASA
- Ticker
- BO4.F
- ISIN
- NO0010657505
- Exchange
- Frankfurt Exchange
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 1,193
- Fiscal year end
- December
- Address
- PO Box 162, Sarpsborg, Norway, 1701
- Phone
- 47 69 11 80 00
- Website
- borregaard.com
About Borregaard ASA
Borregaard ASA engages in the development, production, and marketing of specialized biochemicals and biomaterials in Norway, rest of Europe, Asia, the United States, and internationally. It operates in three segments: BioSolutions, BioMaterials, and Fine Chemicals. The BioSolutions segment develops, produces, and sells biopolymers and biovanillin derived from lignin for agrochemicals, batteries, industrial binders, and construction, as well as to flavor and fragrance companies, and food and beverage industry. Its BioMaterials segment develops, produces, and sells speciality cellulose used as a raw material in the production of cellulose ethers, cellulose acetate, and other specialty products, as well as cellulose fibrils for industrial applications. The Fine Chemicals segment supplies fine chemical intermediates for contrast agents and advanced bioethanol. The company was incorporated in 2012 and is headquartered in Sarpsborg, Norway.
Borregaard ASA management
10- Mr. Tom Erik Foss-JacobsenChief Executive Officer · born 1969
- Mr. Per Bjarne LyngstadChief Financial Officer · born 1961
- Mr. Dag Arthur AasbøSenior Vice President of Public Affairs & Sustainability · born 1961
- Ms. Kari StrandeSenior VP of Human Resources · born 1962
- Mr. Gisle Løhre JohansenExecutive Vice President of Speciality Cellulose & Fine Chemicals · born 1959
- Mr. Ole Gunnar JakobsenExecutive VP of Manufacturing & Technology · born 1969
- Ms. Kristin MisundSenior Vice President of R&D and Business Development · born 1965
- Ms. Liv LongvaSenior Vice President of Procurement & Strategic Sourcing · born 1969
- Mr. Knut-Harald BakkeExecutive Vice President of BioSolutions
- Ms. Guro Elise FredheimChief Technology Officer